文献速递神经肿瘤

复发高级别胶质瘤立体定向放射外科治疗后的失败模式:单中心10年经验

Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years.
PubMed 文献 · Neurosurgery · 2019-01-01

回顾性分析2006年6月至2016年7月单中心47例复发高级别胶质瘤接受立体定向放射外科(SRS)治疗的患者,所有患者均出现治疗失败,85%(40例)为「野内」失败;较高SRS剂量与较长的失败时间相关(每增加1 Gy,风险比=0.80,95%CI 0.67-0.96,P=.016);老年患者远处失败较野内失败显著增加(P=.035)。

要点

  • 复发高级别胶质瘤SRS后多数失败为野内失败(40例,85%)。
  • SRS剂量每增加1 Gy,失败风险比=0.80(95%CI 0.67-0.96,P=.016)。
  • 老年患者远处失败较野内失败显著增加(P=.035),且独立于贝伐珠单抗使用。

核心结论

  • 根据本中心经验,复发高级别胶质瘤SRS后大多数治疗失败为「野内」失败。
  • 老年患者表现为更多的远处失败。
  • 作者认为,以分次或非分次方案给予更高SRS剂量至更大范围可能延长失败时间,尤其在老年人群中。

研究设计与样本

  • 回顾性综述2006年6月至2016年7月在本机构连续接受SRS治疗的47例复发高级别胶质瘤患者的临床、影像和随访信息。
  • 所有患者初诊均为高级别胶质瘤(WHO III级和IV级)。
  • SRS治疗复发后所有患者均出现治疗失败,评估相对于SRS 50%等剂量线的局部、区域和远处失败模式。

主要发现

  • 大多数复发高级别胶质瘤患者SRS后出现「野内」治疗失败(n=40;85%)。
  • 较高SRS剂量与较长的失败时间相关(每增加1 Gy,风险比=0.80;95%CI 0.67-0.96;P=.016)。
  • 老年患者中远处失败较野内失败有统计学显著增加(P=.035)。
  • 该效应独立于贝伐珠单抗使用(比值比=0.54,P=1.0)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) is a treatment modality that is frequently used as salvage therapy for small nodular recurrent high-grade gliomas (HGG). Due to the infiltrative nature of HGG, it is unclear if this highly focused technique provides a durable local control benefit. OBJECTIVE: To determine how demographic or clinical factors influence the pattern of failure following SRS for recurrent high-grade gliomas. METHODS: We retrospectively reviewed clinical, radiographic, and follow-up information for 47 consecutive patients receiving SRS for recurrent HGG at our institution between June 2006 and July 2016. All patients initially presented with an HGG (WHO grade III and IV). Following SRS for recurrence, all patients experienced treatment failure, and we evaluated patterns of local, regional, and distant failure in relation to the SRS 50% isodose line. RESULTS: Most patients with recurrent HGG developed "in-field" treatment failure following SRS (n = 40; 85%). Higher SRS doses were associated with longer time to failure (hazards ratio = 0.80 per 1 Gy increase; 95% confidence interval 0.67-0.96; P = .016). There was a statistically significant increase in distant versus in-field failure among older patients (P = .035). This effect was independent of bevacizumab use (odds ratio = 0.54, P = 1.0). CONCLUSION: Based on our experience, the majority of treatment failures after SRS for recurrent HGG were "in-field." Older patients, however, presented with more distant failures. Our results indicate that higher SRS doses delivered to a larger area as fractioned or unfractioned regimen may prolong time to failure, especially in the older population.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Ene CI, Macomber MW, Barber JK, et al. Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. Neurosurgery. 2019. PMID: 30576476. doi:10.1093/neuros/nyy520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。